{"id":"https://openalex.org/W35282639","doi":null,"title":"Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.","display_name":"Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.","publication_year":2000,"publication_date":"2000-10-01","ids":{"openalex":"https://openalex.org/W35282639","mag":"35282639","pmid":"https://pubmed.ncbi.nlm.nih.gov/11049052"},"language":"en","primary_location":{"id":"pmid:11049052","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11049052","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in oncology","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5030502460","display_name":"Mark Daniel Pegram","orcid":"https://orcid.org/0000-0002-9743-8118","observed_orcids":["https://orcid.org/0000-0002-9743-8118"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"M Pegram","raw_affiliation_strings":["Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA 90095, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Hematology/Oncology, UCLA School of Medicine, Los Angeles, CA 90095, USA","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056234013","display_name":"DJ Slamon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D Slamon","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":7.2784,"has_fulltext":false,"cited_by_count":148,"citation_normalized_percentile":{"value":0.9767764,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"27","issue":"5 Suppl 9","first_page":"13","last_page":"9"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10696","display_name":"Gastric Cancer Management and Outcomes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/her2-neu","display_name":"HER2/neu","score":0.9900000095367432},{"id":"https://openalex.org/keywords/c-erbb-2","display_name":"c-erbB-2","score":0.9269999861717224},{"id":"https://openalex.org/keywords/trastuzumab","display_name":"trastuzumab","score":0.9959999918937683},{"id":"https://openalex.org/keywords/monoclonal-antibody-therapy","display_name":"monoclonal antibody therapy","score":0.847000002861023},{"id":"https://openalex.org/keywords/breast-cancer","display_name":"breast cancer","score":0.9120000004768372},{"id":"https://openalex.org/keywords/her2-amplification","display_name":"HER2 amplification","score":0.8379999995231628},{"id":"https://openalex.org/keywords/signal-transduction","display_name":"signal transduction","score":0.824999988079071},{"id":"https://openalex.org/keywords/tumor-antigens","display_name":"tumor antigens","score":0.6809999942779541},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.515999972820282},{"id":"https://openalex.org/keywords/metastatic-breast-cancer","display_name":"metastatic breast cancer","score":0.8230000138282776}],"concepts":[{"id":"https://openalex.org/C2779786085","wikidata":"https://www.wikidata.org/wiki/Q412616","display_name":"Trastuzumab","level":4,"score":0.9042379856109619},{"id":"https://openalex.org/C542903549","wikidata":"https://www.wikidata.org/wiki/Q422248","display_name":"Monoclonal antibody","level":3,"score":0.7827942967414856},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7070629000663757},{"id":"https://openalex.org/C147483822","wikidata":"https://www.wikidata.org/wiki/Q103537","display_name":"Antigen","level":2,"score":0.652553915977478},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6089543104171753},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.5766956210136414},{"id":"https://openalex.org/C139770010","wikidata":"https://www.wikidata.org/wiki/Q1339807","display_name":"Internalization","level":3,"score":0.5130575895309448},{"id":"https://openalex.org/C2777092746","wikidata":"https://www.wikidata.org/wiki/Q5939625","display_name":"Humanized antibody","level":4,"score":0.4997060298919678},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.456044465303421},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.43254926800727844},{"id":"https://openalex.org/C15152581","wikidata":"https://www.wikidata.org/wiki/Q7833966","display_name":"Transduction (biophysics)","level":2,"score":0.42793944478034973},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.4212813973426819},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.40829312801361084},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.38835203647613525},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3768094480037689},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.25295186042785645},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.19519329071044922},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.16511550545692444},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.15878748893737793},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.07301709055900574}],"mesh":[{"descriptor_ui":"D000068878","descriptor_name":"Trastuzumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D001943","descriptor_name":"Breast Neoplasms","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018719","descriptor_name":"Erb-b2 Receptor Tyrosine Kinases","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D061067","descriptor_name":"Antibodies, Monoclonal, Humanized","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:11049052","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11049052","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Seminars in oncology","raw_type":"Journal Article"},{"id":"mag:35282639","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/11049052","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9789000153541565}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2041875031","https://openalex.org/W2264346970","https://openalex.org/W7100618298","https://openalex.org/W2087238575","https://openalex.org/W1968863785","https://openalex.org/W197699128","https://openalex.org/W2123646476","https://openalex.org/W1964299216","https://openalex.org/W2068425336","https://openalex.org/W2091276845"],"abstract_inverted_index":{"The":[0],"physical":[1],"characteristics":[2,141],"of":[3,35,39,45,47,64,71,76,83,138,142,152,160,173,192,203],"tumor":[4,25,143],"antigens":[5,144],"that":[6,58,131,149],"would":[7],"make":[8],"the":[9,40,48,72,77,129,132,139,150,158,190,201],"most":[10],"ideal":[11,140],"targets":[12],"for":[13],"antibody":[14],"therapeutics":[15],"include":[16],"cell":[17,92],"surface":[18,55],"expression;":[19],"high,":[20],"stable":[21],"expression":[22,30],"levels":[23],"in":[24,31,61,80,184,189],"cells;":[26],"low":[27],"or":[28],"absent":[29],"normal":[32],"tissues;":[33],"lack":[34,44],"a":[36,53,100,112,194,214],"soluble":[37],"form":[38],"antigenic":[41],"target;":[42],"and":[43,90,209],"internalization":[46],"antigen/antibody":[49],"complex.":[50],"HER2/neu":[51,126],"is":[52,59,167,177],"185-kd":[54],"membrane":[56],"protein":[57,134],"overexpressed":[60],"approximately":[62],"25%":[63],"human":[65],"breast":[66,123],"cancers":[67,124],"due":[68],"to":[69,212],"amplification":[70],"HER2":[73,84],"gene.":[74],"Overexpression":[75],"gene":[78],"results":[79],"ligand-independent":[81],"activation":[82],"kinase,":[85],"causing":[86],"mitogenic":[87],"signal":[88,164],"transduction":[89],"increased":[91],"proliferation.":[93],"Consequently,":[94],"patients":[95],"with":[96,125,179],"this":[97],"alteration":[98],"have":[99],"worse":[101],"clinical":[102,119],"prognosis.":[103],"Trastuzumab":[104],"(Herceptin;":[105],"Genentech,":[106],"Inc,":[107],"So.":[108],"San":[109],"Francisco,":[110],"CA),":[111],"humanized":[113],"anti-HER2":[114],"monoclonal":[115,204],"antibody,":[116],"has":[117],"significant":[118],"activity":[120],"against":[121],"metastatic":[122],"overexpression,":[127],"despite":[128],"fact":[130],"p185HER2":[133],"product":[135],"lacks":[136],"some":[137,180],"listed":[145],"above.":[146],"We":[147],"propose":[148],"efficacy":[151],"trastuzumab":[153,176],"may":[154,197],"be":[155,198],"explained":[156],"on":[157,163],"basis":[159],"its":[161,170],"effects":[162],"transduction,":[165],"which":[166],"independent":[168],"from":[169],"immune":[171],"mechanism(s)":[172],"action.":[174],"Furthermore,":[175],"synergistic":[178],"chemotherapeutic":[181],"drugs,":[182],"resulting":[183],"improved":[185],"therapeutic":[186],"efficacy.":[187],"Thus,":[188],"case":[191],"trastuzumab,":[193],"clear":[195],"distinction":[196],"drawn":[199],"between":[200],"use":[202,211],"antibodies":[205],"as":[206],"immuneactive":[207],"agents":[208],"their":[210],"achieve":[213],"desired":[215],"cellular/biochemical":[216],"activity.":[217]},"counts_by_year":[{"year":2025,"cited_by_count":2},{"year":2024,"cited_by_count":3},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2018,"cited_by_count":7},{"year":2017,"cited_by_count":1},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":3}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}